An Open-label Phase I Study of the Safety and Efficacy of MDX-1097, an human IgG1k chimeric monoclonal antibody, in the Treatment of Previously Treated Kappa Light Chain Restricted Multiple Myeloma Patients with Stable Measurable Disease to determine the Safety, Tolerability and Maximum Tolerated Dose

Trial Profile

An Open-label Phase I Study of the Safety and Efficacy of MDX-1097, an human IgG1k chimeric monoclonal antibody, in the Treatment of Previously Treated Kappa Light Chain Restricted Multiple Myeloma Patients with Stable Measurable Disease to determine the Safety, Tolerability and Maximum Tolerated Dose

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs KappaMab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Immune System Therapeutics
  • Most Recent Events

    • 17 Jun 2011 Positive topline tolerability data reported in an Immune System Therapeutics media release.
    • 20 Apr 2009 According to an Immune System Therapeutics media release, 6 patients have been treated to date, and the company is seeking to enroll another nine patients to be treated over the next few months.
    • 20 Apr 2009 Final results are expected later in 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top